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Background - Cardiac metabolism is critical for the functioning of the heart, and disturbance in 
this homeostasis is likely to influence cardiac disorders or cardiomyopathy. Our lab has 
previously shown that sucrose non-fermenting related kinase (SNRK) enzyme, which belongs to 
the AMP-activated kinase (AMPK) family, was essential for cardiac metabolism in mammals. 
Snrk global homozygous knockout (KO) mice die at postnatal day 0, and conditional deletion of 
Snrk in cardiomyocytes (Snrk cmcKO) leads to cardiac failure, and death by 8-10 months. 
Methods and Results - We performed additional cardiac functional studies using 
echocardiography (ECHO), and identified further cardiac functional deficits in Snrk cmcKO 
mice. NMR-based metabolomics analysis identified key metabolic pathway deficits in SNRK 
knockdown cardiomyocytes (CMs) in vitro. Specifically, metabolites involved in lipid 
metabolism and oxidative phosphorylation are altered and perturbations in these pathways can 
result in cardiac function deficits and heart failure. A phosphopeptide-based proteomic screen 
identified Rho-associated kinase (ROCK) as a putative substrate for SNRK and mass spec-based 
fragment analysis confirmed key amino acid residues on ROCK that are phosphorylated by 
SNRK. Western blot analysis on heart lysates from Snrk cmcKO adult mice and SNRK 
knockdown CMs showed increased ROCK activity. In addition, in vivo inhibition of ROCK 
partially rescued the in vivo Snrk cmcKO cardiac function deficits. 
Conclusions - Collectively, our data suggests that SNRK in CMs is responsible for maintaining 
cardiac metabolic homeostasis, which is mediated in part by ROCK and alteration of this 




















Cardiomyopathy is a complex disorder influenced by several factors. Some of these factors 
include impaired endothelial function and sensitivity to various ligands (β-agonists), altered 
intracellular calcium homeostasis, and accumulation of connective tissue such as insoluble 
collagen1. Recently, cardiomyopathy as a consequence of early alterations in cardiac metabolism 
has been proposed, particularly with respect to diabetes2. A potential link between cardiac 
metabolism and function is the Ras homolog family member A (RhoA)-associated kinase 
(ROCK) signaling pathway. The RhoA/ROCK signaling pathway has been implicated in several 
cardiovascular and metabolic disorders such as atherosclerosis, cardiac hypertrophy and 
diabetes3. ROCK is a serine threonine kinase involved in regulating various cellular processes 
such as cell contraction, migration, proliferation, apoptosis/survival and gene 
expression/differentiation4. Interestingly, pharmacological inhibition of RhoA/ROCK activity 
has been shown to improve cardiac function in diabetes-induced cardiomyopathy5. To date 
signaling molecules regulating ROCK activity have primarily been restricted to the RhoA 
pathway. Our lab has identified a novel member of the AMP-activated kinase (AMPK) family 
namely sucrose non-fermenting related kinase (SNRK) that is essential for angiogenesis6, and 
responsible for cardiac metabolism in mammals7. Here, we implicate SNRK as a putative 
regulator of ROCK activity in cardiomyocytes (CMs).  
CMs metabolism is developmentally dynamic in that the fetal heart primarily utilizes 
glucose as its major energy substrate, and during postnatal maturation, the heart switches to 
primarily utilizing fatty acid oxidation to meet its energy demands8, 9. In our previous work7, we 
reported that the global Snrk KO mice die within 24 hours after birth, displayed enlarged hearts, 
and lethality is associated with metabolic defects in cardiac tissues. SNRK maintains metabolic 









homeostasis via regulation of the phosphorylated acetyl-coA carboxylase (pACC)-
phosphorylated AMPK (pAMPK) pathway during this transitional period in development7. 
Furthermore, cardiac specific conditional Snrk KO (Snrk cmcKO) adult mice display severe 
cardiac functional deficits and lethality within 8-10 months. We extend this work further in this 
study, and identified ROCK as a putative substrate for SNRK that contributes to this metabolic 
deficit in the heart. NMR-based metabolomics in human embryonic stem cell derived-CMs and 
signaling studies in both adult heart lysates and cultured CMs collectively imply that SNRK-
mediated ROCK signaling pathway is an important regulator of cardiac function in mammals.  
 
Methods 
Detailed methods are described in the Supplemental Materials. 
Fasudil Rescue 
Male and female mice between six and four months of age were given fasudil (10mg/kg) or 
saline daily for 28 days via intraperitoneal injections. ECHO analysis was performed 
immediately prior to the initial injection and ECHO imaging was repeated at 14 and 28 days. At 
the end of the experiment the mice were euthanized using CO2 and cervical dislocation as per the 
approved IACUC animal protocol. 
Metabolomics Analysis 
CMs treated with either non-silencing shRNA control or shSNRK lentivirus were cultured in 
RPMI containing B27 (no insulin) for 48 h prior to sample collection. Sample collection and 
extraction was performed as described previously in Bhute and Palecek10. 1H NMR spectra were 
acquired using standard NOESYPR1D pulse sequence (RD-90°-t1-90°-tm-90°-acquire) with a 
relaxation delay of 1 s, a mixing time of 100 ms and a pre-scan delay of 30 µs and consisted of 
128 transients or free induction decays (FIDs) collected into 48 K complex data points with a 









spectral width of 12 ppm and an acquisition time of 4 s. FIDs were zero-filled to 128k data 
points and multiplied by an exponential window function (LB=0.5Hz). The chemical shifts were 
referenced to the TMSP peak (δ=0 ppm), using TopSpinTM software (version 3.1, Bruker). 
Spectral processing like phasing, baseline correction and solvent region removal (water and 
DMSO) was performed using ACD/1D NMR processing (Advanced Chemistry Development). 
Targeted profiling11 was performed using ChenomX NMR Suite Profiler (version 7.7, ChenomX 
Inc.) and the concentrations were references to TMSP. Peak annotation was performed based on 
the existing ChenomX library and HMDB12. The metabolite concentrations were exported to an 
Excel file for further analysis.  
The concentration data matrix was normalized by the total concentration of metabolites, 
which was equivalent to normalization by total spectral area in each sample to evaluate the 
metabolite fractions and also to account for the differences in cell number and efficiencies of 
extraction. Statistical and pathway analysis was performed using MetaboAnalyst 3.013. The 
concentration data was auto-scaled (mean centering followed by dividing each variable by the 
standard deviation) prior to principal component analysis (PCA) and student’s t-test was 
performed assuming unequal group variance and α was chosen to be 0.05. Pathway topology 
analysis was performed in MetaboAnalyst’s pathway analysis module using global test algorithm 
for pathway enrichment (adjusted for multiple testings) and out-degree centrality to assess 
importance. The Homo Sapiens library was used for analysis and the metabolic pathways with an 
impact score > 0 and FDR<0.05 were considered to be significantly enriched. 
Protein Kinase Array 
Purified SNRK protein was provided to Invitrogen (Life Technologies) for kinase substrate 
identification service on ProtoArray human protein microarray. In short, SNRK was assayed at 









concentration of 5 nM and 50 nM on ProtoArray human protein microarrays v5.0. All possible 
kinase substrates at each concentration of SNRK were evaluated by their Z-Factor rank within 
the array and were compared to the negative control assay. A protein was defined as being a 
candidate substrate if it met the following conditions: The Z-Factor, or signal-to-noise ratio, was 
great than 0.35 on at least one array, indicating a signal greater than 1.5-fold above the noise. 
The Signal Used value was greater than 2,000 relative units on at least one array probed with 
SNRK and was greater than 2-fold higher than the Signal Used value for the corresponding 
protein in the negative control assay. The replicate spot CV was less than 50% on the 
corresponding array. The inter-assay CV was less than 50%. Additional experimental details are 
available upon request.  
In vitro ROCK Phosphorylation Protocol 
Human umbilical vein endothelial cells (HUVECs) (Lonza CC2519) were lysed with RIPA 
buffer (Sigma) containing complete mini EDTA-free protease inhibitor cocktail (Roche) and 
PhosSTOP phosphatase inhibitor (Roche). Samples were incubated on ice for 20 mins and 
cleared at 13,300 rpm at 4°C for 30 mins. ROCK1 was immunoprecipitated using an anti-
ROCK1 antibody (Cell Signaling Technology) with protein G agarose beads (Thermo 
Scientific). Immunoprecipitates were washed 3x with dilution buffer (10 mM Tris, 130 mM 
NaCl, 0.05% Triton-X-100, 0.1% BSA, protease inhibitors). Additional washes with 50 mM Tris 
(pH 8.0) and Tris-Saline (10 mM Tris HCl, 140 mM NaCl) (pH 8.0) were also performed. The 
Lowry quantification method was used to determine the protein concentration. 
Immunoprecipitated ROCK1 protein was incubated with or without 5 nM to 30 nM purified 
SNRK protein in the presence of 3 μM γ-ATP-32 (Perkin Elmer) and 1 μM ATP (Cell Biolabs) 
in kinase buffer [20 mM HEPES (pH7.7), 20 mM MgCl2, 2 mM DTT, 1X protease inhibitor 









(Roche) and 1X phosphatase inhibitor (Roche)]. The samples were allowed to incubate for 15 
mins at 30°C. After incubation the samples were washed 2-3 times with kinase buffer and re-
suspended in Lamelli sample buffer. 5 μl of the reaction was reserved for radioactive analysis 
and the remaining samples were resolved on a 10% Mini-PROTEAN TGX precast gel (BioRad) 
and subjected to SDS-PAGE. The gel was then dried and exposed to autoradiography film. 
Western Blot (WB) Analysis 
Adult heart tissues were collected immediately after euthanization, and the proteins were isolated 
using homogenization in RIPA buffer (Sigma) with complete mini ETDA-free protease inhibitor 
cocktail (Roche) and PhosSTOP phosphatase inhibitor (Roche) using a Qiagen TissueRuptor. 
Methodologies related to protein estimation, quantitation were described previously7. The 
following antibodies were used: anti- myosin-binding subunit (MBS; BioLegend), anti-phospho 
MBS (pMBS; Cell Signaling Technology/MBL International); anti-ROCK1 (BD Bioscience); 
anti-ROCK2 (BD Bioscience); anti-extracellular signal-regulated kinase (ERK; Cell Signaling 
Technology); anti-phospho ERK (pERK; Cell Signaling Technology); anti-protein kinase B 
(AKT; Cell Signaling Technology); anti-phospho AKT (pAKT; Cell Signaling Technology); 
anti-inhibitor of kappa B kinase (IKK; Cell Signaling Technology); anti-phospho IKK(pIKK; 
Cell Signaling Technology); anti-Tubulin (Sigma), anti-rabbit horseradish peroxidase (HRP; Cell 
Signaling Technology) and anti-mouse HRP (Cell Signaling Technology).  
Statistics 
Student’s unpaired t-test was used for comparison analysis for the cardiomyocyte western blot, 
metabolomics and trichrome staining analysis. Mann-Whitney test was used for comparison 
analysis for the adult heart western blot analysis and all of the ECHO data analysis. The results 
are described as means (± standard error of the mean, SEM). A p-value of p<0.1 was considered 









to be approaching significance. A p-value of p<0.05 was considered significant when comparing 
two parameters. For all of the in vivo and in vitro ROCK signaling and inhibitor experiments a p-
value of p<0.05 was considered to be slightly significant, and a p-value of p<0.0125 was 
considered significant due to p-value correction for multiple comparisons. Sample data values 
for the trichrome staining analysis and the western blot experiments are provided in Table S1. 
Sample data values for the metabolomics data are provided in Table S2. 
 
Results 
Snrk cardiac (cmcKO) conditional knockout adult mice show myocardial dysfunction and 
increased cardiac fibrosis  
Previously, our lab assessed the role of Snrk in mammalian development, and concluded that 
SNRK is essential for cardiac metabolism7. In that study, we generated and validated the global 
and cardiac-specific (MYH6CRE)14 conditional Snrk cmcKO mouse reagents7. Homozygous loss 
of Snrk (LoxP/LoxP) in CMs results in lethality between 8-10 months of age and heterozygous 
loss of Snrk (LoxP/WT) showed lethality shortly after one year of age. Echocardiography 
(ECHO) analysis on 6 month old adult male mice showed significant enlargement of the left 
ventricle inner diameter (LVID) in systole (s) and diastole (d), significant increase in end 
diastolic volume (EDV) and end systolic volume (ESV), significant decrease in the ejection 
fraction (EF) and the fractional shortening (FS) in the Snrk cmcKO (MYH6CRE Snrk LoxP/LoxP) 
mice compared to the CRE negative littermates7. We now performed strain and strain rate 
imaging analysis (Fig. 1A), which showed that Snrk cmcKO display significantly worsening 
strain patterns including decreased radial strain (p=0.0286), increased circumferential strain 
(p=0.0286), decreased strain rates S (p=0.0286). The strain rate changes correlates with a 
decrease in systolic function. The Snrk cmcKO mice also display an increased strain rate E 









(p=0.0286) that is associated with worsening diastolic function. Furthermore, the pulmonary 
acceleration time (PAT) (p=0.0571), ejection time (ET) (p=0.0571) (Fig. 1B) and right 
ventricular outflow tract time velocity-integrals (TVI) were also decreased in Snrk cmcKO 
(p=0.0571) (Fig. 1C). All together, these findings are consistent with a dilated cardiomyopathy 
with a resultant increase in pulmonary artery pressure. 
We next investigated whether myocardial stiffening and impaired cardiac function could 
be the result of increase in extracellular matrix deposition, a phenomenon described as 
myocardial fibrosis15. We performed trichrome staining on Snrk cmcKO heart tissue sections 
(Fig. 1D). Snrk cmcKO showed a significant increase in fibrosis staining (CRE neg 10.38%, 
cmcKO 19.32% p=0.0212) (Fig. 1E and Table S1). These data indicates deformation in the heart 
segments resulting in altered myocardial function and suggest that Snrk in CMs is critical for 
maintaining heart contractility. 
SNRK knockdown CMs in vitro show defective metabolism 
To investigate what might be amiss in CMs in the absence of SNRK, we investigated changes in 
metabolism in SNRK knockdown CMs in vitro since previous data on Snrk cmcKO mice showed 
cardiac metabolic defects7. CMs treated with either non-silencing shRNA control or efficacy-
confirmed shSNRK lentivirus was subjected to NMR-based metabolomics measurement as 
described in the methods section. The heat maps (Fig. 2A) and subsequent graphical 
representation (Fig. 2B) clearly depict extensive metabolic changes in SNRK knockdown CMs. 
Metabolites that significantly increased (Fig. S1A) and decreased (Fig. S1B) in SNRK 
knockdown CMs have been indicated. Among the increased metabolites, we observed significant 
increase in multiple osmolytes including glycerophosphocholine (Fold Change: 1.44, p=0.0046) 
and taurine (Fold Change: 1.27, p=0.038). We also observed an increase in a few essential amino 









acids including valine and threonine while, majority of the non-essential amino acids including 
alanine (p<0.1), asparagine, aspartate, glutamate, and glutamine showed a significant decrease 
due to SNRK knockdown (p<0.05). This indicates significant changes in amino acid-related 
metabolic pathways, which is also observed in pathways analysis (Fig. 2C). Interestingly, 
glycerol was significantly increased due to SNRK knockdown relative to control (Fold Change: 
1.38, p=0.018).  Glycerol can serve as substrate for energy in cardiomyocyte16 and we observe 
several other metabolites associated with energy metabolism including citrate, fumarate, malate, 
succinate (p<0.05), pyruvate and NAD (p<0.1) to be significantly reduced due to SNRK 
knockdown in CMs. This indicates that SNRK can play a crucial role in energy homeostasis in 
CMs.   
Further pathway topology analysis (Fig. 2C) and metabolite set enrichment analysis (Fig. 
2D) suggested significant changes in alanine, aspartate and glutamate metabolism (p=0.002) 
(Fig. 2C and S2), citrate cycle (p=3.47E-06) (Fig. 2C and S3), taurine and hypotaurine 
metabolism (p=0.002), aminoacyl t-RNA biosynthesis (p=0.009) and glycine, serine and 
threonine metabolism (p=0.01) (Fig. 2C). Specific metabolites and amounts that changed in 
SNRK knockdown CMs are indicated in supplemental Tables S2 and S3. Taking the in vivo and 
in vitro data together, SNRK in CMs plays an instrumental role in maintaining metabolic 
homeostasis, which is critical for the normal functioning of the heart.  
ROCK is a putative substrate of SNRK 
To identify signaling proteins responsible for the cardiac function deficits observed in Snrk 
cmcKO mice in vivo, we performed a phosphopeptide proteomic screen using pure SNRK 
protein generated in the lab. Human histidine tagged SNRK protein was generated in bacteria 
(Fig. S4), purified (Fig. S4A), and confirmed by mass spectral (MS) analysis (23% peptide 









coverage) and western blotted for SNRK antibody (Fig. S4D). Using this purified SNRK protein 
(Fig. S4E), we outsourced the kinase profiling to Life Technologies. An in vitro protein kinase 
experiment was performed on 9,000 N-terminal GST fusion proteins on an array at two SNRK 
protein concentrations (5 and 50 nM). This screen identified Rho-associated kinase 1 (ROCK1) 
as one of the top hits along with several members of the transforming growth factor- (TGF-) 
signaling pathway (ACVR1, ACVRL1, SMAD3, BMPR2) that showed 2-fold or more 
phosphorylation compared to negative control (Table. S4). We confirmed the ROCK1 
phosphorylation in vitro using a ROCK kinase assay (Fig. 3A). ROCK1 protein was 
immunoprecipitated (IPed) from human umbilical vein endothelial cells (HUVECs) (Fig. 3A, IP 
blot), and was incubated with purified SNRK protein in the presence of radiolabeled phosphate 
(P32). As shown (Fig. 3A, lane 2), a P32-labeled band is observed in the lane with IPed ROCK 
plus SNRK protein at the correct size for the ROCK1 protein, which was quantified in three 
independent experiments (Fig. 3A, Quantitation panel). In addition, we performed multi-stage 
fragmentation tandem Mass Spectrometry on ROCK1 IPed from HUVECs in the presence or 
absence of SNRK. The ROCK1 band was excised and subjected to in-gel tryptic digestion. The 
resulting peptides were analyzed by multi-stage fragmentation mass spectral analysis17. The data 
for ROCK1 identified residues S27, T237, S479 (Fig. S5, blue circles) that resides in the N-
terminal region. These sites are distinct from those reported in the literature (Fig. S5 magenta 
circles) or previously identified using proteomic approaches (Fig. S5, yellow highlighted 
residues). Collectively, this data suggests that ROCK1 is a direct target of SNRK, and 
phosphorylation of ROCK by SNRK at specific residues is likely to influence its downstream 
activity.  
 We next evaluated ROCK activity by determining the amount of phospho-Threonine 853  









in the myosin-binding subunit (pMBS) of myosin light chain phosphatase, a key enzyme in the 
RhoA-ROCK muscle contraction signaling cycle. We performed western blots for ROCK1, 
ROCK2 and pMBS protein levels in Snrk cmcKO adult (Fig. 3B) heart lysates. Of the proteins 
investigated, pMBS levels were higher in adult Snrk cmcKO hearts (MYH6CRE SNRK L/L) 
(Fig. 3B, p=0.1) compared to CRE negative controls. We also investigated SNRK knockdown 
CMs in vitro for pMBS, and observed an increase that was not significant (Fig. 4A, p=0.36, 
n=3). Interestingly, when control and shSNRK knockdown CMs were treated with the ROCK 
inhibitor Y27632 (Fig. 4A), there was a slightly significant decrease in pMBS levels compared to 
control treated shSNRK knockdown CMs (40.75% p=0.041, n=3). Specific sample data values 
are indicated in supplemental Tables S1. Collectively, the phosphoproteomic analysis and 
signaling data suggests that ROCK is a substrate of SNRK, and ROCK activity is attenuated by 
SNRK in vivo and in vitro in CMs. 
SNRK-ROCK signaling in cardiomyocytes 
We next investigated signaling pathways that can be regulated by ROCK signaling such as 
protein kinase b alpha (AKT) and mitogen-activated protein kinase (ERK) in both in vivo Snrk 
cmcKO mice (Fig. 3B), and in vitro SNRK knockdown CMs (Fig. 4B-D). ROCK is known to 
regulate the phosphoinositide 3-kinase (PI3K)-AKT pathway by activating the 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) phosphatase called phosphatase and tensin 
homolog (PTEN), which results in a reduction in pAKT levels18, 19. In addition, ROCK has also 
been shown to influence ERK signaling in smooth muscle cells20. Western blot analysis was 
conducted on Snrk WT and cmcKO hearts lysates as well as control and shSNRK knockdown 
cells with and without the ROCK inhibitor Y27632. Loss of SNRK in the heart resulted in 
decreased pAKT (Fig. 3B, 46.15%, p=0.1, n=3) and the AKT downstream effector pIKK (Fig. 









3B, 44.62%, p=0.1, n=3), which suggests decreased AKT signaling in the Snrk cmcKO hearts. 
We also observed a trend towards increased pERK (Fig. 3B, 183.47%, p=0.2, n=3) in the heart 
lysates. Specific sample data values are indicated in supplemental Tables S1. 
Surprisingly knockdown of SNRK in CMs resulted in a non-significant change in pAKT 
(Fig. 4B, 171.07%, p=0.136, n=4) and pERK (Fig. 4D, 311.64%, p=0.212), and a significant 
increase in pIKK (Fig. 4C, 254.38%, p=0.012, n=3). Inhibition of ROCK signaling using the 
ROCK inhibitor Y27632 was able to significantly decrease the pMBS levels in the shSNRK CM 
compared to the control treated shSNRK CM (Fig. 4A, Control 123.35%, shSNRK 40.75% 
p=0.041, n=3). pAKT, pERK and pIKK levels did not significantly change in the presence of the 
ROCK inhibitor (Fig. 4C) suggesting that ROCK signaling is not the only molecule involved in 
regulating pAKT, pERK and pIKK signaling in cultured CMs. These results collectively suggest 
that SNRK directly influences ROCK signaling in CMs in vivo and in vitro.  
SNRK-ROCK signaling is required for normal cardiac function 
Altered ROCK signaling has been previously implicated cardiac hypertrophy and ventricular 
remodeling4, 21, 22. To determine whether the cardiac defects observed in the Snrk cmcKO mice 
are attributed to increased ROCK activation, Snrk WT and Snrk cmcKO mice were treated with 
the ROCK inhibitor fasudil23. To assess changes in cardiac function, ECHO was conducted 
before drug treatment and after 4 weeks of daily fasudil or saline injection (Fig. 5 and Table S5). 
Fasudil treatment in Snrk cmcKO mice resulted in stabilization of EF and FS phenotypes, from 
55.55% (cmcKO-Fasudil) and 50.66% (cmKO-Saline) EF and 24.77%-22.7% FS before 
treatment to 53% EF and 23.23% FS after fasudil treatment compared to the saline treated Snrk 
cmcKO mice which displayed continued declines in EF (44.55% p=0.0286) and FS (18.9% 
p=0.0286). EDV did not show a significant change in the Snrk cmcKO mice (0.0064) treated 









with fasudil compared to baseline (0.0070, p=0.6905) whereas EDV continued to increase in the 
saline treated Snrk cmcKO mice from 0.0066 at baseline to 0.0082 at 4 week (p=0.0286).  ESV 
did not increase in the fasudil treated Snrk cmcKO mice but did in the saline treated mice 
(baseline 0.0029 to 4 weeks 0.0046, p=0.0286) indicating a preserved EF in the fasudil treated 
mice. IVRT showed a similar trend with a slight decrease in the fasudil treated Snrk cmcKO 
mice (baseline 14.45 to 4 weeks 12.41, p=0.3413), and an increase in Snrk cmcKO saline treated 
mice (baseline 12.4 to 4 weeks 13.22, p=0.0286). These data indicates that increased ROCK 
activity is involved in generating the cardiac functional deficits observed in the Snrk cmcKO 
mice and that inhibition of ROCK results in cardiac functional improvements. 
 
Discussion 
In this study, we have identified that a member of the AMPK family namely SNRK influences 
ROCK signaling to maintain cardiac function in the adult. Snrk was first identified in 3T3-L1 
differentiated adipocyte cells24, and compared to Ampk1 and Ampk2, Snrk expression in white 
adipose tissue, brown adipose tissue, heart and brain is significantly higher25. The expression 
profile of SNRK, and the family that it belongs to suggest a role for this enzyme during high 
metabolic needs like the heart contraction and relaxation cycles. Indeed in our previous report 7, 
we identified that SNRK is a critical regulator of metabolic function during embryonic 
cardiovascular development, and identified the metabolic pAMPK-pACC signaling pathway 
deregulation in the heart. These results directly support current NMR-based metabolomic 
analysis data in SNRK knockdown CMs, which shows decreased metabolites such as those 
involved in alanine, aspartate and glutamate metabolism (Fig. S2), as well as citric acid cycle 
metabolism (Fig. S3), and increases in metabolites involved in lipid synthesis such as glycerol 
(Fig S1)26 which are processes directly influenced by pAMPK-pACC signaling27, 28. Interestingly 









perturbations in cardiac metabolic output have been observed in patients with heart failure29, 30. 
In normal hearts, the primary metabolic energy source is derived by lipid metabolism/fatty acid 
oxidation and in failing hearts the metabolic substrate changes to glucose metabolism31. 
Furthermore, accumulation of lipids (free fatty acids) in the failing heart can create additional 
metabolic stress by increasing energy uncoupling and proton leakage and decreasing energy 
production32, 33. In the SNRK knockdown CMs, we did not observe any significant changes in 
glycolysis or glucose metabolism but we did observe significant alterations in oxidative 
phosphorylation and lipid metabolism indicating an important role for SNRK in cardiac 
metabolism and loss of SNRK can result in a phenotypes similar to those observed during 
cardiac failure. In addition, taurine and hypotaurine metabolism was found to be increased in the 
Snrk knockdown CMs indicating the activation of compensatory mechanisms to increased 
osmotic stress34, 35, and further supporting the notion that SNRK is an important regulator of 
cardiac cellular homeostasis.  
 To assess the contribution of SNRK to cardiac function, we conditionally deleted Snrk in 
CMs in vivo using MYH6CRE14 mouse line. The Snrk cmcKO mice develop cardiomyopathy 
and die at 8-10 months of age7. The 6 months ECHO studies showed changes in left ventricular 
dimensions and decreased ventricular function consistent with a dilated cardiomyopathy. Left 
heart failure often result in increased pulmonary artery pressures and our ECHO-Doppler 
interrogation of right heart hemodynamics corroborate this relationship. These mice over time 
progressively show increased fibrosis and cardiac stiffening, phenotypes associated with 
dysregulated ROCK signaling36, 37. Indeed, we identified two key molecules namely the TGF- 
signaling pathway and ROCK signaling pathways in our SNRK substrate screen both of which 
have been implicated in cardiac stiffening and fibrosis37. We posit that SNRK’s involvement in 









the two signaling pathways may not be mutually exclusive since both have been implicated in 
CMs function previously. For example, TGF-3 and ALK2 regulate ROCK1 expression during 
valvuloseptal endocardial cushion formation38, and up regulation of bone morphogenetic protein-
2 (BMP-2), antagonized TGF-1/ROCK-enhanced cardiac fibrotic signal through activation of 
Smurf1/Smad6 complex37. In this study, we only focused on ROCK because of the 
overwhelming evidence suggesting ROCK as a cardiovascular risk factor39, and its role in 
cardiovascular physiology and pathophysiology4. 
ROCKs’ are ubiquitously expressed proteins, and both isoforms ROCK1 and ROCK2 are 
expressed in the heart40. Signaling mechanisms associated with contraction in the vascular 
smooth muscle cells (SMCs) in the heart are well studied for ROCK. Briefly, intracellular Ca2+ 
level increases through activated G-protein coupled receptors, which in turn stimulate 
downstream phosphorylation of myosin light chain kinase (MLCK) (activating), and 
phosphorylation of the myosin binding subunit (MBS also known as MYPT1) of myosin light 
chain phosphatase (MLCP) (inactivating). The exchange factor RhoA is the chief upstream 
activator of ROCK1 to date, and has been the established regulator of this pathway4, the net 
result of which is contraction of SMCs. Our studies suggest SNRK is a second player upstream 
of ROCK but whether the phosphorylation directly activates or inhibits ROCK activity or 
whether additional proteins along with SNRK are required for altered ROCK activity is currently 
unknown. Our data suggests that SNRK is a negative regulator of ROCK signaling, and loss of 
SNRK increases ROCK activity in CMs. Indeed loss of SNRK in Snrk cmcKO adult (6 months) 
mice showed higher levels of pMBS reinforcing the hypothesis that phosphorylation of ROCK1 
by SNRK may be inhibitory (Fig. 3). The converse experiment would be the overexpression or 
gain of SNRK in cardiac tissue, which should decrease ROCK activity and consequences 









associated with it. The resulting phenotype would include improved cardiac function since 
ROCK1 is necessary for the transition from cardiac hypertrophy to failure41. Indeed two abstracts 
report that SNRK overexpression in the heart improves cardiac metabolic efficiency and 
response to myocardial ischemia42, 43, which support our predictive hypothesis. 
We also examined the activation status of additional downstream effectors of ROCK such 
as AKT and ERK and identified altered in vivo expression levels of pAKT and pERK further 
suggesting that ROCK activity are altered in vivo when SNRK is absent (Figs. 3 and 6). 
Interestingly, we did not see a significant difference in the in vitro expression levels of pAKT, 
pERK and pMBS in SNRK knockdown CMs. These observations could be attributed to the 
inherent differences between in vitro culturing conditions and in vivo responses that contain 
additional non-CM cell types influencing the experimental readout. Additional in vitro studies 
are necessary to specifically address these differences. 
To assess whether attenuation of ROCK signaling in Snrk cmcKO mice is consequential, 
we treated Snrk cmcKO mice with the ROCK inhibitor fasudil23. Prior to treatment, the Snrk 
cmcKO already displayed cardiac functional defects. After 4 weeks of treatment with the 
inhibitor the Snrk cmcKO mice began showing signs of improved cardiac function and 
stabilization of the phenotype compared to the untreated Snrk cmcKO mice that continued to 
show decreased cardiac function (Fig. 5 and Table S5). These findings suggest that some of the 
cardiac functional deficits observed in the Snrk cmcKO mice are most likely a result increased 
ROCK activity and that SNRK regulation of ROCK signaling in an important component of 
normal cardiac function.  
 In summary, our data suggests that an AMPK family member SNRK is a critical 
metabolic sensor in cardiac tissues, and directly influences ROCK signaling in CMs, effects that 









directly contribute to maintaining cardiac metabolic homeostasis and cardiac functional output in 
mammals.  
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Figure 1: Cardiomyocyte-conditional SNRK null mice (Snrk cmcKO) ECHO results. ECHO 
was performed on 6 month adult Snrk WT and cmcKO males as described in the materials and 
methods. Panel A describes strain and strain rate imaging analyses by ECHO. Panel B indicates 
isovolumic relaxation time (IVRT) msec, a parameter for diastolic function, ratio of mitral peak 
velocity of early filling (E) m to early diastolic mitral annular velocity (e') (E/e' ratio), pulmonary 
acceleration time (PAT) msec, ejection time (ET) msec and ratio of PAT to ET. Panel C shows 
time-velocity integrals (TVI) cm along with mitral peak velocity (E) m/s and diastolic mitral 
annular velocity (e’) m/s. Panel D are representative images of Gomori’s Trichrome staining in 
CRE negative or cardiomyocyte specific conditional null (MYH6CRE SNRK L/L) adult mouse 
hearts. Panel E, shows average percent collagen staining in CRE negative MYH6CRE SNRK 
L/L adult mouse hearts. The number of mice per group equals 3-5. *=p<0.05, #=p<0.1. Scale bar 
= 1mm  
  
Figure 2: Loss of SNRK results in altered metabolomic profiles. Panel A. Heat map depicting 
the altered identified metabolites in non-silencing shRNA control (CNT) and shSNRK 









knockdown (SNRK) cardiomyocytes. Panel B Score Plot analysis for principle components (PC) 
between the non-silencing shRNA control (CNT) red and shSNRK knockdown (SNRK) green 
cardiomyocytes. Panel C Pathway topology analysis. Panel D. Metabolite set enrichment 
analysis was used to identify significantly enriched pathways (p<0.05). 
 
Figure 3: SNRK phosphorylation of ROCK, and influences on its activity in Snrk cmcKO adult 
hearts. Panel A shows direct phosphorylation of immunoprecipitated ROCK1 from human 
umbilical vein endothelial cells. Quantitation of the radioactive band in A is shown, and the 
successful immunoprecipitation of ROCK1 is demonstrated with the ROCK antibody on IPed 
lysates. Arrow denotes ROCK1 band. Data represents 3-4 independent experiments. Panel B 
western blot quantitation on lysates from cardiomyocyte-deleted SNRK adult hearts. Panel C 
representative western blot images from 4 independent heart lysates. The number of mice per 
group equals 3.  
 
Figure 4: Loss of Snrk in cardiomyoctyes results in increased ROCK activity. Western blots 
were performed on cardiomyocytes as described in materials and methods. Panel A-D western 
blot quantification of cardiomyocytes treated with water (Control), or 5 uM ROCK Inhibitor 
Y27632. Data represents 3-4 independent experiments. *=p<0.05, **=p<0.0125. 
 
Figure 5: Inhibition of ROCK signaling improved cardiac function in cardiomyocyte-conditional 
SNRK null mice (Snrk cmcKO). ECHO was performed on 6-4 month adult male and female 
Snrk WT and Snrk cmcKO mice immediately prior to treatment and after 4 weeks. The mice 
received daily injections of saline or fasudil as described in the materials and methods. Panel A 









and B describes left ventricular (LV) function parameters EF % and FS %. Panel C and D 
describes the EDV and ESV which were normalized to body weight (BW). Panel E indicates the 
IVRT msec. Panel F is a representative M-Mode images from the mouse hearts at baseline or 
after 4 weeks of daily fasudil or saline injections. There were 2 males and 2 females in the saline 
treated Snrk cmcKO and Snrk WT groups and 2 males and 3 females in the fasudil treated Snrk 
cmcKO and Snrk WT groups. See Table S5 for complete data set. 
  
Figure 6: Proposed model for the mechanism of SNRK regulation of ROCK activity. ROCK is a 
major downstream effector of the small GTPase RhoA. Upon activation, ROCK can influence 
cellular contraction by phosphorylating myosin-binding subunit (MBS, also known as MYPT-1) 
of the myosin phosphatase complex. Phosphorylation of the myosin phosphatase complex 
renders the complex inactive and it is no longer able to remove the active phosphate group from 
phosphorylated myosin light chain (pMLC). Phosphorylated MLC is active and able to promote 
cellular contraction. SNRK regulates this process by modulating ROCK activity via 
phosphorylation of ROCK. ROCK can also influence ERK phosphorylation and nuclear 
localization as well as activate PTEN, which in turns inhibits the PI3K pathway resulting in the 
inhibition of phospho-AKT. 
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Mouse	  Experiments.	  The	  mice	  were	  housed	  in	  the	  Medical	  College	  of	  Wisconsin	  Biological	  Resource	  
Center,	  and	  all	  experiments	  were	  performed	  in	  accordance	  with	  an	  IACUC	  approved	  animal	  procedure	  
protocol	  1022.	  The	  Snrk	  cmcKO	  adult	  mice	  were	  generated	  from	  MYH6CRE	  positive	  Snrk	  LoxP/wild	  type	  
(WT)	  males	  mated	  to	  Snrk	  LoxP/LoxP	  females.	  When	  possible	  age	  and	  litter	  matched	  male	  and	  female	  
mice	  were	  used	  for	  each	  animal	  experiment.	  Mixed	  backcrossed	  animals	  were	  used	  for	  all	  of	  the	  mouse	  
experiments.	  Primer	  information	  for	  mouse	  genotyping	  were	  provided	  previously1.	  	  
	  
Human	  Cardiomyocyte	  System.	  Directed	  differentiation	  of	  CMs	  from	  human	  embryonic	  stem	  cells	  
(hESCs)	  is	  described	  in	  previous	  studies2,	  3.	  Briefly,	  hESCs	  maintained	  on	  matrigel	  in	  mTeSR1	  were	  
dissociated	  into	  single	  cells	  using	  Accutase	  (Life	  Technologies)	  at	  37°C	  for	  5	  min	  and	  then	  were	  seeded	  
onto	  a	  matrigel-­‐coated	  12-­‐well	  plate	  at	  100,000-­‐200,000	  cell/cm2	  in	  mTeSR1	  supplemented	  with	  5	  μM	  
Y-­‐27632	  (Tocris)	  for	  24	  h.	  After	  24	  h,	  fresh	  mTeSR1	  medium	  was	  used	  every	  day	  to	  expand	  stem	  cells.	  
When	  cells	  achieved	  a	  density	  of	  500,000	  cell/cm2,	  cells	  were	  treated	  with	  12	  μM	  CHIR99021	  
(Selleckchem)	  in	  RPMI/B27	  without	  insulin	  for	  24	  h	  (day	  0	  to	  day	  1).	  The	  medium	  was	  changed	  to	  
RPMI/B27	  without	  insulin	  on	  day	  1,	  followed	  by	  5	  μM	  IPW2	  (Tocris)	  treatment	  on	  day	  3.	  During	  the	  day	  
5	  medium	  change	  IWP2	  was	  removed.	  Cells	  were	  maintained	  in	  the	  RPMI/B27	  starting	  from	  day	  7,	  with	  
the	  medium	  changed	  every	  3	  days.	  
	  
Lentiviral	  Transduction	  of	  CMs	  and	  Drug	  Treatments.	  Day	  six	  CMs	  differentiated	  from	  hESCs	  were	  
dissociated	  into	  single	  cells	  with	  Accutase	  at	  37°C	  for	  5-­‐8	  mins,	  and	  then	  were	  spun	  down	  into	  aliquots	  
of	  1.5×106	  cells.	  Cells	  were	  re-­‐suspended	  in	  30	  μL	  concentrated	  lentivirus	  medium	  in	  the	  presence	  of	  6	  
μg/mL	  polybrene	  (Sigma),	  and	  then	  incubated	  at	  room	  temperature	  for	  10	  mins.	  At	  the	  end	  of	  
	  	   2	  
incubation,	  2	  mL	  of	  DMEM/10%	  FBS	  +	  5	  μM	  Y-­‐27632	  (Tocris)	  was	  added	  and	  the	  suspension	  was	  
transferred	  into	  2	  wells	  of	  a	  12-­‐well	  plate	  pre-­‐coated	  with	  Matrigel,	  and	  incubated	  at	  37°C,	  5%	  CO2	  
overnight.	  The	  medium	  was	  replaced	  with	  fresh	  DMEM/10%	  FBS	  on	  the	  second	  day	  of	  lentiviral	  
infection,	  and	  afterwards	  cells	  were	  treated	  with	  water	  (control),	  and	  5	  μM	  Y27632	  for	  9	  days.	  Two	  
days	  later,	  infected	  cells	  were	  selected	  and	  enriched	  for	  3	  days	  based	  on	  resistance	  to	  1	  μg/mL	  
puromycin	  (Sigma).	  48	  h	  before	  sample	  collection,	  cells	  were	  switched	  to	  RPMI	  containing	  B27	  (no	  
insulin)	  supplement.	  On	  day	  15,	  the	  cells	  were	  rinsed	  with	  PBS	  and	  the	  proteins	  were	  collected	  for	  
western	  blot	  analysis	  as	  previously	  described1,	  4,	  5.	  
	  
Echocardiography	  and	  Image	  Analysis.	  Transthoracic	  echocardiography	  was	  performed	  in	  anesthetized	  
(2%	  isoflurane)	  six	  months	  old	  litter	  matched	  males.	  An	  investigator	  (L.M.H)	  who	  was	  blinded	  to	  the	  
study	  groups	  performed	  the	  measurements	  and	  data	  analyses.	  A	  comprehensive	  2D	  transthoracic	  
echocardiogram	  with	  Doppler	  was	  performed	  on	  animals	  using	  Animals	  were	  studied	  with	  a	  
commercially	  available	  echocardiographic	  system	  (Vivid	  7,	  General	  Electric,	  Wauwatosa,	  WI),	  with	  an	  11-­‐
MHz	  M12-­‐L	  linear	  array	  transducer.	  A	  comprehensive	  2D	  transthoracic	  echocardiogram	  with	  Doppler	  
was	  performed	  from	  the	  cardiac	  short	  axis	  of	  the	  left	  ventricle	  at	  the	  papillary	  muscle	  level.	  Using	  the	  
anatomical	  M-­‐mode	  feature	  of	  the	  Vivid	  7	  echo,	  an	  M-­‐mode	  display	  was	  generated	  from	  raw	  data	  2D	  
images	  of	  the	  short-­‐axis	  of	  the	  left	  ventricle	  at	  the	  level	  of	  the	  papillary	  muscle	  with	  the	  line	  selected	  
passing	  through	  the	  anterior	  and	  inferior	  segments.	  Ejection	  fraction	  %	  (EF)	  was	  measured	  using	  left	  
ventricle	  end	  diastolic	  volume	  (LVEDV)	  and	  left	  ventricle	  end	  systolic	  volume	  (LVESV)	  using	  the	  formula	  
EF=	  LVEDV	  -­‐	  LVESV/	  LVEDV	  x	  100.	  Fractional	  shortening	  %	  (FS)	  was	  calculated	  with	  the	  formula:	  left	  
ventricle	  end	  diastolic	  dimension	  (LVEDD)-­‐left	  ventricle	  end	  systolic	  dimension	  (LVESD)/LVEDD	  x	  100.	  To	  
assess	  diastolic	  function,	  pulse	  wave	  Doppler	  was	  used	  to	  assess	  transmitral	  inflow	  velocities	  in	  the	  
apical	  4-­‐chamber	  view	  to	  obtain	  E	  velocities	  and	  isovolumic	  relaxation	  times	  (IVRT).	  	  Tissue	  Doppler	  was	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used	  to	  assess	  tissue	  motion	  velocity	  from	  the	  mitral	  annulus	  to	  obtain	  e’	  velocities.	  E/e’	  is	  a	  calculated	  
ratio.	  Pulse	  wave	  Dopplers	  was	  also	  used	  to	  sample	  velocities	  at	  the	  right	  ventricular	  outflow	  tract	  to	  
assess	  for	  pulmonary	  acceleration	  time	  (PAT)	  and	  ejection	  time	  (ET).	  For	  two-­‐dimensional	  strain	  analysis,	  
the	  images	  were	  processed	  with	  EchoPac	  Q	  analysis	  software,	  (General	  Electric,	  Wauwatosa,	  WI).	  A	  
cardiac	  cycle	  was	  defined	  from	  the	  peak	  of	  one	  R	  wave	  to	  the	  peak	  of	  the	  following	  R	  wave.	  Unless	  
stated	  otherwise,	  for	  every	  measurement,	  three	  consecutive	  cardiac	  cycles	  were	  measured,	  and	  the	  
average	  used	  for	  reporting.	  The	  method	  has	  been	  previously	  described6.	  	  Briefly,	  for	  radial	  and	  
circumferential	  strain,	  the	  endocardial	  border	  was	  traced	  in	  an	  end-­‐systolic	  frame	  in	  the	  short-­‐axis	  view	  
at	  the	  mid	  ventricle	  as	  identified	  by	  the	  prominent	  papillary	  muscles.	  The	  software	  automatically	  
selected	  6	  equidistant	  tissue-­‐tracking	  regions	  of	  interest	  in	  the	  myocardium.	  The	  outer	  border	  was	  
adjusted	  to	  approximate	  the	  epicardial	  border.	  The	  computer	  then	  provided	  a	  profile	  of	  radial	  
(myocardial	  deformation	  toward	  the	  center)	  and	  circumferential	  (myocardial	  deformation	  along	  the	  
curvature)	  strain	  (%)	  with	  time.	  	  
	  
Purification	  of	  SNRK.	  Cloned	  full	  length	  human	  SNRK	  sequence	  was	  transformed	  into	  BL21(DE3)	  
competent	  cells	  (New	  England	  Biolabs).	  Bacterial	  cells	  were	  cultured	  overnight	  at	  37°C	  in	  LB	  and	  induced	  
with	  1mM	  IPTG	  and	  incubated	  at	  25°C	  for	  6	  h.	  The	  bacteria	  were	  then	  pelleted	  and	  the	  supernatant	  was	  
removed.	  The	  pelleted	  bacteria	  were	  lysed	  using	  a	  bacterial	  lysis	  buffer	  containing	  13	  mL	  BPER	  (Pierce	  
Technologies),	  50	  μL	  DNAse	  (2	  U/μL),	  41	  μL	  lysozyme	  (50	  mg/mL)	  and	  40	  μL	  1M	  MgCl2,	  protease	  
inhibitor	  (Roche).	  The	  pellet	  was	  incubated	  with	  the	  lysis	  buffer	  at	  room	  temperature	  for	  15	  mins.	  One	  
tablet	  of	  complete	  Mini	  EDTA-­‐free	  protease	  inhibitor	  cocktail	  (Sigma)	  was	  add	  to	  the	  mixture	  and	  
centrifuged	  at	  7,600	  x	  g	  for	  15	  mins.	  The	  supernatant	  was	  removed	  and	  dialyzed	  in	  a	  Slide-­‐A-­‐Lyzer	  with	  
10K	  molecular	  cutoff	  (ThermoFisher)	  overnight	  at	  room	  temperature	  in	  1X	  binding	  buffer	  (57mM	  
NaH2PO4	  pH8.0,	  300mM	  NaCl).	  The	  dialyzed	  supernatant	  was	  subjected	  to	  Nickel-­‐NTA	  column	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purification,	  and	  pure	  protein	  eluted	  in	  10	  mM,	  25	  mM	  and	  250	  mM	  Imidazole	  elution	  buffer.	  Samples	  
of	  the	  fractions	  were	  resolved	  on	  a	  10%	  Mini-­‐PROTEAN	  TGX	  precast	  gel	  (BioRad),	  subjected	  to	  SDS-­‐PAGE	  
and	  subsequently	  stained	  with	  coomassie	  blue.	  Fractions	  eluted	  with	  250	  mM	  Imidazole	  were	  
concentrated	  using	  Amicon	  Ultra	  15	  mL	  50	  MWL,	  kDa	  centrifugal	  filter	  units	  (EMD	  Millipore).	  Purified	  
protein	  was	  subjected	  to	  Mass	  Spectometry	  analysis	  for	  identity	  confirmation.	  SNRK	  kinase	  activity	  was	  
confirmed	  using	  the	  ADP-­‐Glo	  Kinase	  Assay	  (Promega).	  In	  short,	  purified	  SNRK	  protein	  was	  incubated	  
with	  10mM	  ATP,	  different	  amounts	  Histone	  H3	  (0,	  500ng,	  1000ng,	  2000ng,	  4000ng)	  and	  kinase	  reaction	  
buffer.	  ADP-­‐Glo	  reagent	  was	  then	  added	  to	  stop	  the	  kinase	  reaction	  and	  deplete	  the	  unconsumed	  ATP.	  
After	  40	  mins,	  the	  kinase	  detection	  reagent	  was	  added	  to	  convert	  the	  ADP	  to	  ATP	  for	  luciferase	  
detection	  of	  the	  ATP.	  The	  luciferase	  was	  measured	  using	  a	  plate-­‐reading	  luminometer	  
(SpectraMaxGeminiEM,	  Molecular	  Devices)	  with	  SoftMax	  Pro	  software.	  
	  
Identification	  of	  SNRK	  Candidate	  Substrates.	  All	  possible	  kinase	  substrates	  at	  each	  concentration	  of	  
SNRK	  were	  evaluated	  by	  the	  Z-­‐Factor	  rank	  within	  the	  array	  and	  were	  compared	  to	  the	  negative	  control	  
assay.	  A	  protein	  was	  defined	  as	  being	  a	  candidate	  substrate	  for	  SNRK	  if	  it	  met	  the	  following	  conditions:	  
1)	  The	  Z-­‐Factor,	  or	  signal-­‐to-­‐noise	  ratio,	  was	  greater	  than	  0.35	  on	  at	  least	  one	  assay,	  indicating	  a	  signal	  
greater	  than	  1.5-­‐fold	  above	  the	  noise.	  2)	  The	  Signal	  Used	  value	  was	  greater	  than	  2,000	  relative	  unites	  on	  
at	  least	  one	  array	  probed	  with	  SNRK	  and	  was	  greater	  than	  2-­‐fold	  higher	  than	  the	  Signal	  Used	  value	  for	  
the	  corresponding	  protein	  in	  the	  negative	  control	  assay.	  3)	  The	  replicate	  spot	  coefficient	  of	  variation	  
(CV)	  was	  less	  than	  50%	  on	  the	  corresponding	  array.	  4)	  The	  inter-­‐assay	  CV	  was	  less	  than	  50%.	  
	  
Mass	  Spectral	  Analysis.	  Immunoprecipitated	  ROCK1	  protein	  was	  incubated	  with	  or	  without	  50	  nM	  
purified	  SNRK	  protein	  in	  the	  presence	  of	  4	  μM	  ATP	  (Cell	  Biolabs)	  in	  kinase	  buffer	  [20	  mM	  HEPES	  (pH	  
7.7),	  20	  mM	  MgCl2,	  2	  mM	  DTT,	  1X	  protease	  inhibitor	  (Roche)	  and	  1X	  phosphatase	  inhibitor	  (Roche)].	  The	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samples	  were	  allowed	  to	  incubate	  for	  15	  mins	  at	  30°C.	  After	  incubation	  the	  samples	  were	  washed	  2-­‐3	  
times	  with	  kinase	  buffer	  and	  re-­‐suspended	  in	  Lamelli	  sample	  buffer.	  The	  samples	  were	  resolved	  using	  
gel	  electrophoresis	  and	  then	  subjected	  to	  in-­‐gel	  tryptic	  digestion	  followed	  by	  Mass	  Spectral	  analysis.	  
Mass	  spectral	  analysis	  was	  performed	  on	  an	  LTQ-­‐Orbitrap	  Velos	  mass	  spectrometer	  (Thermo	  
Scientific,	  Waltham,	  MA,	  USA)	  coupled	  with	  a	  nanoAQUITY	  ultraperformance	  liquid	  chromatographer	  
(UPLC)	  (Waters	  Corp.)	  interfaced	  with	  a	  nanoelectrospray	  ion	  source.	  Peptide	  separation	  was	  carried	  out	  
on	  a	  capillary	  column	  built	  in-­‐house	  with	  5µm	  C18	  nanoparticles	  to	  10	  cm	  long	  column	  with	  75	  µm	  inner	  
diameter	  tubing.	  The	  fused	  silica	  capillaries	  (Polymicro	  Technologies,	  Phoenix,	  AZ,	  USA)	  for	  the	  columns	  
were	  pulled	  by	  a	  micropipette	  puller	  P-­‐2000	  (Sutter	  Instrument	  Company,	  CA,	  USA)	  and	  packed	  with	  C18	  
resin	  using	  a	  bomb-­‐loader.	  The	  solvents	  A	  and	  B	  used	  for	  chromatographic	  separation	  of	  peptides	  were	  
2%	  acetonitrile	  in	  0.1%	  formic	  acid	  and	  98%	  acetonitrile	  in	  0.1%	  formic	  acid,	  respectively.	  The	  peptides	  
injected	  onto	  the	  microcapillary	  column	  were	  resolved	  at	  the	  rate	  of	  200	  nl/min,	  using	  the	  following	  
gradient	  conditions:	  0	  to	  10	  min,	  2	  to	  20%	  B;	  120	  min,	  40%	  B;	  135	  min,	  60%	  B;	  150	  min,	  70%	  B;	  158	  min,	  
98%B,	  which	  was	  held	  for	  4	  min	  and	  then	  switched	  to	  98%	  A	  and	  held	  for	  another	  18	  min.	  The	  ions	  
eluted	  from	  the	  column	  were	  electrosprayed	  at	  a	  voltage	  of	  1.70	  kV.	  The	  ion	  transfer	  temperature	  was	  
kept	  at	  250°C.	  No	  auxiliary	  or	  sheath	  gas	  was	  used.	  
	   Survey	  full-­‐scan	  mass	  spectrometry	  (MS)	  spectra	  (m/z,	  300	  to	  2,000)	  were	  recorded	  in	  the	  
Orbitrap	  analyzer	  at	  a	  resolution	  of	  30,000	  followed	  by	  tandem	  mass	  spectrometry	  (MS/MS)	  of	  the	  10	  
most	  intense	  peptide	  ions	  in	  the	  linear	  ion	  trap	  analyzer.	  Neutral	  loss-­‐triggered	  multistage	  activation	  for	  
simultaneous	  fragmentation	  of	  neutral	  loss	  product	  and	  precursor	  was	  enabled	  at	  m/z	  of	  -­‐98,	  -­‐49	  and	  -­‐
32.6	  relative	  to	  the	  precursor	  ion,	  corresponding	  to	  a	  neutral	  loss	  of	  phosphate	  moiety	  from	  +1,	  +2,	  and	  
+3	  charged	  ions.	  The	  chromatographic	  and	  mass	  spectral	  functions	  were	  controlled	  using	  the	  Xcalibur	  
data	  system	  (ThermoFinnigan,	  Palo	  Alto,	  CA,	  USA).	  Peptides	  were	  identified	  using	  the	  Mascot	  search	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algorithm	  for	  human	  protein	  database	  at	  a	  global	  false-­‐discovery	  rate	  of	  5%.	  The	  resulting	  files	  were	  
evaluated	  using	  Visualize	  tool7.	  
	  
Tissue	  Sectioning,	  Staining	  and	  Image	  Analysis.	  Adult	  mouse	  hearts	  were	  fixed	  in	  4%	  
paraformaldehyde/PBS	  for	  1	  to	  2	  days	  at	  4°C.	  After	  fixation	  tissues	  were	  washed	  extensively	  in	  PBS	  and	  
embedded	  in	  paraffin	  or	  sucrose/OCT	  as	  previously	  described1.	  Seven	  micron	  thick	  sections	  were	  stained	  
with	  Gomori’s	  Trichrome	  staining	  and	  Hematoxylin	  counter	  staining.	  The	  microscopic	  images	  of	  the	  
entire	  tissue	  section	  were	  scanned	  at	  40x	  magnification	  using	  the	  Nanozoomer	  2.0-­‐HT	  (Hamamatsu,	  
Japan)	  digital	  slide	  scanning	  system	  (Children’s	  Research	  Institute’s	  Imaging	  Core).	  The	  amount	  of	  
fibrosis	  was	  quantified	  using	  software	  assisted,	  unbiased	  microimage	  quantification	  method.	  The	  
scanned	  images	  were	  imported	  into	  Visiopharm	  software	  (Denmark)	  and	  using	  the	  imager	  module,	  
three	  20x	  ROI	  images	  were	  extracted	  from	  left,	  center	  and	  right	  regions	  of	  the	  heart.	  Collagen	  positive	  
regions	  (navy	  blue	  stains)	  were	  identified	  by	  thresholding	  the	  specific	  image	  channel	  filter	  and	  the	  rest	  
of	  the	  tissue	  (muscle	  -­‐	  stained	  red	  and	  nucleus	  -­‐	  stained	  deep	  blue)	  classified	  as	  tissue	  region	  with	  total	  
tissue	  region	  defined	  as	  sum	  of	  muscle,	  nuclear	  and	  collagen	  region	  without	  any	  interstitial	  space.	  All	  
original	  images	  were	  processed	  with	  this	  preset	  thresholds	  and	  linear	  Bayesian	  classification	  to	  generate	  
a	  processed	  image.	  Total	  collagen	  positive	  area	  per	  ROI	  was	  measured	  in	  microns	  and	  represented	  as	  a	  
percentage	  of	  the	  total	  tissue	  area.	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Supplemental	  Figures	  and	  Tables	  
	  
Figure	  S1.	  Loss	  of	  SNRK	  in	  cardiomyocytes	  results	  in	  altered	  metabolic	  profiles.	  Panel	  A	  shows	  the	  
upregulated	  metabolites	  and	  B	  shows	  the	  downregulated	  metabolites.	  *p<0.05,	  #	  p<0.1.	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Figure	  S2.	  Loss	  of	  SNRK	  in	  cardiomyocytes	  results	  in	  altered	  alanine,	  aspartate,	  and	  glutamate	  
metabolism.	  Panel	  A	  is	  the	  Pathway	  topology	  analysis	  impact	  score,	  p	  value	  and	  FDR.	  Panel	  B	  is	  the	  
pathway	  view	  showing	  the	  corresponding	  Alanine,	  aspartate	  and	  glutamate	  metabolic	  pathways.	  The	  
matched	  metabolites	  are	  highlighted	  according	  to	  their	  P	  values.	  Panel	  C	  is	  the	  normalized	  
concentration	  fro	  the	  individual	  metabolites.	  *p<0.05,	  #	  p<0.1.	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Figure	  S3.	  Loss	  of	  SNRK	  in	  cardiomyocytes	  results	  in	  altered	  Citric	  acid	  cycle	  metabolites.	  Panel	  A	  is	  the	  
Pathway	  topology	  analysis	  impact	  score,	  p	  value	  and	  FDR.	  Panel	  B	  is	  the	  pathway	  view	  showing	  the	  
altered	  metabolites	  in	  the	  citric	  acid	  cycle.	  The	  matched	  metabolites	  are	  highlighted	  according	  to	  their	  P	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Figure	  S4.	  Human	  histidine	  tagged	  SNRK	  protein	  generation	  and	  purification.	  Panel	  A	  indicates	  a	  SDS-­‐
PAGE	  gel	  resolving	  the	  different	  fractions.	  Lys:	  lysate,	  FT:	  flow	  through.	  Numbers	  indicate	  the	  fraction	  
number	  post	  10	  mM	  (1-­‐5),	  25	  mM	  (6-­‐8)	  and	  250	  mM	  (9-­‐11)	  imidazole	  elution.	  The	  numbers	  on	  top	  of	  
each	  lane	  corresponds	  to	  fraction	  elution	  profile	  in	  panel	  B.	  Panel	  B	  indicates	  elution	  profile	  and	  arrows	  
indicate	  imidazole	  elution	  points	  with	  each	  number	  corresponding	  to	  concentration	  of	  imidazole.	  Only	  
IPTG	  induced	  bacterial	  profile	  is	  shown.	  Panel	  C	  shows	  fraction	  #10	  (black	  asterisks),	  re-­‐purified	  a	  second	  
round	  on	  Nickel	  NTA	  column	  and	  eluted	  with	  250	  mM	  imidazole.	  Panel	  D	  shows	  a	  western	  blot	  with	  
SNRK	  antibody	  in	  uninduced	  (UI)	  and	  induced	  (I)	  lysate.	  Red	  arrow	  indicates	  the	  full-­‐length	  protein	  and	  
black	  arrow	  indicates	  degraded	  products.	  Numbers	  on	  left	  of	  each	  gel	  indicate	  protein	  size	  markers	  in	  
kDa.	  Panel	  E	  indicates	  the	  three	  fractions	  from	  250	  mM	  imidazole	  purification	  that	  were	  subsequently	  
concentrated	  and	  run	  on	  Coomassie-­‐stained	  SDS-­‐PAGE	  gel	  before	  the	  final	  product	  was	  sent	  for	  array	  
experiment.	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Figure	  S5.	  Mass	  spectral	  (MS)	  analysis	  of	  the	  SNRK	  mediated	  phosphorylation	  sites	  on	  ROCK1.	  MS	  
analysis	  was	  used	  to	  identify	  the	  residues	  on	  ROCK	  which	  are	  phosphorylated	  by	  SNRK	  in	  vitro.	  Full	  
length	  ROCK	  was	  incubated	  with	  or	  without	  SNRK.	  The	  SNRK	  dependent	  phosphorylated	  residues	  are	  
depicted	  with	  a	  blue	  circle	  and	  the	  previously	  published	  phosphorylated	  residues	  are	  depicted	  with	  a	  
magenta	  circle.	  MS	  identified	  amino	  acids	  are	  shown	  in	  bold	  red	  (current	  study),	  and	  the	  yellow	  
highlighted	  residues	  were	  previously	  identified	  but	  not	  yet	  confirmed	  by	  proteomic	  analysis	  on	  
PhosphoSitePlus.	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Tricrhome	  Staining	  
	   	   	   	   	   	  
Genotype	   Average	  %	  Collagen	  
	   	   	   	   	  
CRE	  Negative	  1	   6.60	  
	   	   	   	   	  
CRE	  Negative	  2	   7.24	  
	   	   	   	   	  
CRE	  Negative	  3	   12.25	  
	   	   	   	   	  
CRE	  Negative	  4	   15.45	  
	   	   	   	   	  
Average	   10.38	  
	   	   	   	   	  
SEM	   2.07	  
	   	   	   	   	  
MYH6CRE	  SNRK	  L/L	  1	   17.62	  
	   	   	   	   	  
MYH6CRE	  SNRK	  L/L	  2	   21.70	  
	   	   	   	   	  
MYH6CRE	  SNRK	  L/L	  3	   18.63	  
	   	   	   	   	  
Average	   19.32	  
	   	   	   	   	  
SEM	   1.23	  
	   	   	   	   	  
	   	   	   	   	   	   	  Adult	  Heart	  Lysate	  Western	  Blot	  Quantification	  
	   	  
%	  Relative	  Intensity	   Ratio	  
Genotype	   ROCK1/Tubulin	   ROCK2/Tubulin	   pMBS/MBS	   pERK/ERK	   pAKT/AKT	   pIKK/IKK	  
CRE	  Negative	  1	   100.00	   100.00	   100.00	   100.00	   100.00	   100.00	  
CRE	  Negative	  2	   105.91	   129.55	   105.39	   118.63	   100.26	   101.15	  
CRE	  Negative	  3	   94.09	   70.45	   94.61	   81.37	   99.74	   98.85	  
Average	   100.00	   100.00	   100.00	   100.00	   100.00	   100.00	  
SEM	   3.41	   17.06	   3.11	   10.75	   0.15	   0.66	  
MYH6CRE	  SNRK	  L/L	  1	   68.89	   96.79	   121.84	   168.36	   41.77	   23.39	  
MYH6CRE	  SNRK	  L/L	  2	   123.78	   107.34	   112.14	   105.87	   67.13	   51.21	  
MYH6CRE	  SNRK	  L/L	  3	   76.34	   55.27	   134.66	   276.17	   29.53	   59.24	  
Average	   89.67	   86.47	   122.88	   183.47	   46.15	   44.62	  
SEM	   17.19	   15.89	   6.52	   49.74	   11.07	   10.86	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Table	  S1.	  Individual	  data	  values	  for	  the	  Trichome	  staining	  and	  Western	  blot	  analysis.	  
	   	  
Cardiomyocyte	  Lysate	  Western	  Blot	  Quantification	  
%	  Relative	  Intensity	   Ratio	  
	  
Genotype	   pMBS/MBS	   pAKT/AKT	   pIKK/IKK	   pERK/ERK	  
	   	  
Non-­‐Sliencing-­‐Control	  1	   100.00	   100.00	   100.00	   100.00	  
	   	  
Non-­‐Sliencing-­‐Control	  2	   100.00	   100.00	   100.00	   100.00	  
	   	  
Non-­‐Sliencing-­‐Control	  3	   100.00	   100.00	   100.00	   100.00	  
	   	  
Non-­‐Sliencing-­‐Control	  4	   No	  Sample	   100.00	   No	  Sample	   100.00	  
	   	  
Average	   100.00	   100.00	   100.00	   100.00	  
	   	  
SEM	   0.00	   0.00	   0.00	   0.00	  
	   	  
Non-­‐Sliencing-­‐Rock	  Inh	  1	   35.48	   744.30	   78.44	   88.78	  
	   	  
Non-­‐Sliencing-­‐Rock	  Inh	  2	   99.99	   337.96	   268.41	   193.19	  
	   	  
Non-­‐Sliencing-­‐Rock	  Inh	  3	   64.57	   16.79	   244.95	   61.88	  
	   	  
Non-­‐Sliencing-­‐Rock	  Inh	  4	   No	  Sample	   No	  Sample	   No	  Sample	   27.17	  
	   	  
Average	   66.68	   366.35	   197.27	   92.75	  
	   	  
SEM	   18.65	   210.49	   59.80	   35.78	  
	   	  
shSNRK-­‐Control	  1	   83.02	   168.95	   249.50	   545.89	  
	   	  
shSNRK-­‐Control	  2	   161.12	   280.99	   318.23	   335.43	  
	   	  
shSNRK-­‐Control	  3	   125.92	   81.92	   195.43	   70.86	  
	   	  
shSNRK-­‐Control	  4	   No	  Sample	   161.20	   No	  Sample	   46.28	  
	   	  
Average	   123.35	   173.26	   254.39	   249.62	  
	   	  
SEM	   22.58	   40.94	   35.54	   118.48	  
	   	  
shSNRK-­‐Rock	  Inh	  1	   8.24	   301.99	   344.53	   19.71	  
	   	  
shSNRK-­‐Rock	  Inh	  2	   56.12	   118.15	   653.82	   80.37	  
	   	  
shSNRK-­‐Rock	  Inh	  3	   57.90	   9.26	   176.38	   32.75	  
	   	  
shSNRK-­‐Rock	  Inh	  4	   No	  Sample	   No	  Sample	   No	  Sample	   8.58	  
	   	  
Average	   40.75	   143.13	   391.58	   35.36	  
	   	  
SEM	   16.26	   85.42	   139.82	   15.80	  
	   	  




















acid	   Choline	  
Citric	  
acid	   Creatine	  
CNT-­‐1	   0.11	   4.66	   4.48	   1.83	   2.62	   0.52	   0.54	   0.13	   0.36	   0.08	  
CNT-­‐2	   0.12	   4.39	   3.90	   2.01	   2.41	   0.52	   0.51	   0.12	   0.29	   0.11	  
CNT-­‐3	   0.11	   4.50	   4.75	   1.88	   2.70	   0.56	   0.54	   0.14	   0.32	   0.12	  
Average	   0.11	   4.52	   4.38	   1.91	   2.58	   0.54	   0.53	   0.13	   0.32	   0.10	  
SEM	   0.00	   0.08	   0.25	   0.05	   0.09	   0.01	   0.01	   0.01	   0.02	   0.01	  
shSNRK-­‐1	   0.11	   4.64	   3.87	   1.93	   2.23	   0.44	   0.48	   0.15	   0.24	   0.17	  
shSNRK-­‐2	   0.10	   3.90	   3.80	   1.84	   2.16	   0.40	   0.47	   0.14	   0.21	   0.16	  
shSNRK-­‐3	   0.10	   4.48	   3.37	   1.65	   2.06	   0.38	   0.42	   0.14	   0.25	   0.08	  
Average	   0.10	   4.34	   3.68	   1.80	   2.15	   0.41	   0.46	   0.14	   0.23	   0.14	  


















one	   Glycerol	   Glycine	  
Isobutyr
ic	  acid	  
CNT-­‐1	   0.12	   2.78	   0.04	   1.28	   5.88	   4.74	   0.41	   0.31	   3.26	   0.03	  
CNT-­‐2	   0.13	   2.48	   0.04	   0.73	   5.15	   4.87	   0.42	   0.27	   3.14	   0.03	  
CNT-­‐3	   0.19	   2.53	   0.04	   0.65	   5.48	   4.88	   0.41	   0.24	   3.39	   0.04	  
Average	   0.15	   2.60	   0.04	   0.89	   5.50	   4.83	   0.41	   0.27	   3.26	   0.03	  
SEM	   0.02	   0.09	   0.00	   0.20	   0.21	   0.04	   0.00	   0.02	   0.07	   0.00	  
shSNRK-­‐1	   0.17	   2.95	   0.03	   0.64	   4.37	   4.34	   0.40	   0.35	   3.56	   0.06	  
shSNRK-­‐2	   0.19	   2.57	   0.03	   0.48	   4.04	   4.42	   0.36	   0.41	   3.32	   0.04	  
shSNRK-­‐3	   0.11	   2.75	   0.03	   0.75	   3.62	   4.22	   0.38	   0.37	   3.16	   0.04	  
Average	   0.16	   2.76	   0.03	   0.62	   4.01	   4.33	   0.38	   0.38	   3.35	   0.05	  
SEM	   0.02	   0.11	   0.00	   0.08	   0.22	   0.06	   0.01	   0.02	   0.11	   0.01	  	   	  
























CNT-­‐1	   0.81	   42.69	   0.56	   0.38	   0.92	   0.26	   3.76	   0.51	   0.35	   0.05	  
CNT-­‐2	   0.85	   46.56	   0.63	   0.46	   0.83	   0.25	   2.97	   0.46	   0.38	   0.05	  
CNT-­‐3	   0.84	   42.72	   0.62	   0.40	   1.07	   0.28	   3.75	   0.48	   0.36	   0.05	  
Average	   0.83	   43.99	   0.60	   0.41	   0.94	   0.26	   3.49	   0.48	   0.36	   0.05	  
SEM	   0.01	   1.29	   0.02	   0.02	   0.07	   0.01	   0.26	   0.01	   0.01	   0.00	  
shSNRK-­‐1	   0.79	   44.02	   0.61	   0.42	   0.30	   0.26	   4.29	   0.55	   0.34	   0.05	  
shSNRK-­‐2	   0.84	   47.45	   0.67	   0.40	   0.43	   0.29	   3.80	   0.48	   0.30	   0.04	  
shSNRK-­‐3	   0.92	   47.92	   0.72	   0.44	   0.33	   0.27	   4.05	   0.57	   0.33	   0.04	  
Average	   0.85	   46.47	   0.67	   0.42	   0.36	   0.27	   4.05	   0.53	   0.32	   0.04	  




























CNT-­‐1	   0.20	   4.11	   0.09	   0.25	   1.66	   1.25	   1.07	   1.13	   0.88	   0.21	  
CNT-­‐2	   0.19	   3.92	   0.10	   0.29	   1.61	   1.30	   1.13	   1.00	   1.01	   0.23	  
CNT-­‐3	   0.18	   4.28	   0.08	   0.29	   1.73	   1.27	   0.99	   1.08	   1.03	   0.22	  
Average	   0.19	   4.10	   0.09	   0.27	   1.67	   1.27	   1.06	   1.07	   0.97	   0.22	  
SEM	   0.01	   0.11	   0.00	   0.01	   0.04	   0.02	   0.04	   0.04	   0.05	   0.01	  
shSNRK-­‐1	   0.16	   4.53	   0.08	   0.24	   1.85	   1.56	   0.99	   1.01	   1.45	   0.17	  
shSNRK-­‐2	   0.15	   4.34	   0.09	   0.27	   1.77	   1.44	   0.90	   0.94	   1.41	   0.19	  
shSNRK-­‐3	   0.12	   4.18	   0.08	   0.26	   1.63	   1.67	   0.89	   1.06	   1.37	   0.16	  
Average	   0.14	   4.35	   0.08	   0.26	   1.75	   1.56	   0.93	   1.01	   1.41	   0.17	  
SEM	   0.01	   0.10	   0.00	   0.01	   0.06	   0.07	   0.03	   0.03	   0.02	   0.01	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ne	   L-­‐Valine	  
	   	   	  CNT-­‐1	   1.86	   0.55	   1.27	   0.13	   0.25	   0.19	   0.31	  
	   	   	  CNT-­‐2	   1.64	   0.47	   0.95	   0.15	   0.25	   0.17	   0.35	  
	   	   	  
CNT-­‐3	   1.98	   0.48	   1.20	   0.13	   0.24	   0.21	   0.36	  
	   	   	  
Average	   1.83	   0.50	   1.14	   0.14	   0.25	   0.19	   0.34	  
	   	   	  
SEM	   0.10	   0.03	   0.10	   0.01	   0.00	   0.01	   0.01	  
	   	   	  
shSNRK-­‐1	   2.55	   0.55	   1.09	   0.12	   0.26	   0.16	   0.36	  
	   	   	  
shSNRK-­‐2	   2.32	   0.61	   0.85	   0.10	   0.28	   0.13	   0.37	  
	   	   	  
shSNRK-­‐3	   2.11	   0.61	   0.87	   0.11	   0.23	   0.15	   0.40	  
	   	   	  
Average	   2.33	   0.59	   0.94	   0.11	   0.26	   0.14	   0.38	  
	   	   	  
SEM	   0.13	   0.02	   0.08	   0.01	   0.01	   0.01	   0.01	  
	   	   	  	  
Table	  S2.	  Individual	  data	  values	  for	  the	  Metabolomics	  data	  analysis.	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Compound	  Name	   HMDB	   Fold	  change	   pvalue	   Compound	  Name	   HMDB	  
Fold	  
change	   pvalue	  
3-­‐Methyl-­‐2-­‐oxovaleric	  acid	   HMDB00491	   -­‐1.1045	   0.0579	   L-­‐Leucine	   HMDB00687	   1.1034	   0.1765	  
4-­‐Hydroxyproline	   HMDB00725	   -­‐1.2171	   0.1779	   L-­‐Lysine	   HMDB00182	   1.0209	   0.7521	  
Acetic	  acid	   HMDB00042	   -­‐1.0403	   0.5029	   L-­‐Methionine	   HMDB00696	   1.0318	   0.5483	  
Benzoic	  acid	   HMDB01870	   -­‐1.1618	   0.0293	   L-­‐Phenylalanine	   HMDB00159	   -­‐1.0657	   0.3195	  
Choline	   HMDB00097	   1.0970	   0.1850	   L-­‐Proline	   HMDB00162	   1.0506	   0.3155	  
Citric	  acid	   HMDB00094	   -­‐1.3709	   0.0187	   L-­‐Serine	   HMDB00187	   -­‐1.0653	   0.2615	  
Creatine	   HMDB00064	   1.3478	   0.2904	   L-­‐Threonine	   HMDB00167	   1.1904	   0.0452	  
D-­‐Glucose	   HMDB00122	   -­‐1.4290	   0.2758	   L-­‐Tryptophan	   HMDB00929	   -­‐1.2443	   0.0691	  
Formic	  acid	   HMDB00142	   1.0608	   0.3383	   L-­‐Tyrosine	   HMDB00158	   1.0252	   0.6969	  
Fumaric	  acid	   HMDB00134	   -­‐1.2891	   0.0320	   L-­‐Valine	   HMDB00883	   1.1174	   0.1000	  
Glutathione	   HMDB00125	   -­‐1.0884	   0.0604	   Malic	  acid	   HMDB00744	   -­‐2.6446	   0.0018	  
Glycerol	   HMDB00131	   1.3832	   0.0170	   Myoinositol	   HMDB00211	   1.1585	   0.1364	  
Glycerophosphocholine	   HMDB00086	   1.4451	   0.0012	   N-­‐Acetyl-­‐L-­‐aspartic	  acid	   HMDB00812	   1.1035	   0.1920	  
Glycine	   HMDB00123	   1.0256	   0.5675	   NAD	   HMDB00902	   -­‐1.1205	   0.0677	  
Isobutyric	  acid	   HMDB01873	   1.3424	   0.1492	   O-­‐Phosphoethanolamine	   HMDB00224	   1.0601	   0.1671	  
L-­‐Acetylcarnitine	   HMDB00201	   -­‐1.2026	   0.0890	   Pantothenic	  acid	   HMDB00210	   -­‐1.0767	   0.3511	  
L-­‐Alanine	   HMDB00161	   -­‐1.1898	   0.0777	   Phosphocreatine	   HMDB01511	   1.0772	   0.7406	  
L-­‐Arginine	   HMDB00517	   -­‐1.0563	   0.3586	   Phosphorylcholine	   HMDB01565	   -­‐1.3449	   0.0126	  
L-­‐Asparagine	   HMDB00168	   -­‐1.1999	   0.0135	   Pyroglutamic	  acid	   HMDB00267	   1.2219	   0.0139	  
L-­‐Aspartic	  acid	   HMDB00191	   -­‐1.3150	   0.0044	   Pyruvic	  acid	   HMDB00243	   -­‐1.1466	   0.0589	  
L-­‐Glutamic	  acid	   HMDB00148	   -­‐1.3717	   0.0079	   Succinic	  acid	   HMDB00254	   -­‐1.2730	   0.0104	  
L-­‐Glutamine	   HMDB00641	   -­‐1.1167	   0.0024	   Taurine	   HMDB00251	   1.2745	   0.0350	  
L-­‐Isoleucine	   HMDB00172	   1.0221	   0.6772	   Uridine	  diphosphate-­‐N-­‐
acetylglucosamine	  
HMDB00290	   -­‐1.3140	   0.0225	  
L-­‐Lactic	  acid	   HMDB00190	   1.0563	   0.2365	  
	  
Table	  S3.	  Full	  metabolomic	  data	  set.	  HMDB:	  human	  metabolic	  database	  ID	  number.	  
	  
	  




















BC036089.1	   IOH27267	   2714	   0.71	   0.92	   5.27E-­‐02	   5%	   33%	   50	  nM	   31	   87.7	   MLLT3	  
BC000250.1	   IOH4515	   4650	   0.79	   1.76	   1.75E-­‐02	   5%	   3%	   50	  nM	   1423	   3.3	   NME3	  
BC000633.1	   	  	   37106	   0.54	   12.01	   7.75E-­‐04	   11%	   0%	   5	  nM	   6431	   5.8	   TTK	  
BC000633.1	   	  	   10465	   0.84	   4.31	   2.98E-­‐03	   4%	   2%	   50	  nM	   4132	   2.5	   TTK	  
BC005403.1	   IOH61712	   2200	   0.65	   0.70	   7.47E-­‐02	   6%	   10%	   50	  nM	   887	   2.5	   C11orf57	  
BC008668.1	   IOH9808	   15077	   0.86	   4.71	   4.25E-­‐03	   3%	   9%	   5	  nM	   4132	   3.6	   GAK	  
BC008668.1	   IOH9808	   2758	   0.78	   0.94	   4.37E-­‐02	   2%	   4%	   50	  nM	   1181	   2.3	   GAK	  
BC010357.1	   IOH14260	   3147	   0.58	   1.11	   3.72E-­‐02	   9%	   5%	   50	  nM	   842	   3.7	   RSRC1	  
BC012576.1	   IOH12217	   3144	   0.62	   1.11	   4.10E-­‐02	   8%	   26%	   50	  nM	   1134	   2.8	   BAZ2B	  
BC014298.1	   IOH13449	   2232	   0.70	   0.71	   8.14E-­‐02	   7%	   0%	   50	  nM	   620	   3.6	   PRKRIP1	  
BC016330.1	   IOH14709	   3175	   0.82	   1.12	   3.60E-­‐02	   1%	   37%	   50	  nM	   606	   5.2	   RAD51AP1	  
BC017070.1	   IOH11214	   2106	   0.85	   0.66	   7.54E-­‐02	   1%	   14%	   50	  nM	   521	   4.0	   CLUAP1	  
BC020726.1	   IOH12969	   2249	   0.60	   0.45	   2.13E-­‐01	   2%	   3%	   5	  nM	   753	   3.0	   SCEL	  
BC020810.1	   IOH27927	   17729	   0.97	   7.46	   1.09E-­‐03	   1%	   3%	   50	  nM	   8713	   2.0	   CHD2	  
BC024208.1	   IOH12635	   3825	   0.85	   1.41	   2.24E-­‐02	   2%	   5%	   50	  nM	   1788	   2.1	   RBM23	  
BC036434.1	   IOH62212	   4915	   0.88	   1.34	   4.02E-­‐02	   0%	   4%	   5	  nM	   1446	   3.4	   VRK2	  
BC053878.1	   IOH28978	   19734	   0.60	   6.25	   2.69E-­‐03	   9%	   7%	   5	  nM	   3803	   5.2	   ZAP70	  
BC057783.1	   IOH29271	   6275	   0.77	   2.48	   8.68E-­‐03	   6%	   6%	   50	  nM	   2768	   2.3	   SFRS2B	  
NM_001005158.1	   IOH57124	   16956	   0.96	   7.14	   1.07E-­‐03	   1%	   2%	   50	  nM	   8020	   2.1	   SFMBT1	  
NM_001204.3	   	  	   3430	   0.42	   0.81	   4.17E-­‐02	   1%	   12%	   5	  nM	   841	   4.1	   BMPR2	  
NM_001396.2	   	  	   7538	   0.93	   2.21	   1.68E-­‐02	   1%	   6%	   5	  nM	   3478	   2.2	   DYRK1A	  
NM_002005.2	   IOH21035	   5454	   0.48	   1.52	   4.08E-­‐02	   15%	   9%	   5	  nM	   1402	   3.9	   FES	  
NM_002031.2	   IOH56137	   9494	   0.70	   2.85	   1.18E-­‐02	   9%	   0%	   5	  nM	   2768	   3.4	   FRK	  
NM_002031.2	   IOH56137	   3096	   0.68	   1.09	   3.69E-­‐02	   6%	   2%	   50	  nM	   1315	   2.4	   FRK	  
NM_002904.4	   IOH14621	   2048	   0.46	   0.39	   2.93E-­‐01	   9%	   17%	   5	  nM	   1003	   2.0	   RDBP	  
NM_003609.2	   IOH4232	   3524	   0.47	   1.27	   3.02E-­‐02	   4%	   2%	   50	  nM	   984	   3.6	   HIRIP3	  
NM_004103.2	   	  	   3888	   0.81	   1.00	   6.82E-­‐02	   3%	   11%	   5	  nM	   664	   5.9	   PTK2B	  
NM_005197.2	   IOH56874	   7269	   0.77	   2.91	   6.37E-­‐03	   6%	   8%	   50	  nM	   3354	   2.2	   FOXN3	  
NM_005902.1	   IOH27044	   5846	   0.58	   2.28	   1.05E-­‐02	   2%	   9%	   50	  nM	   1420	   4.1	   SMAD3	  
NM_005902.1	   IOH27044	   4092	   0.58	   1.06	   6.83E-­‐02	   10%	   1%	   5	  nM	   1181	   3.5	   SMAD3	  
NM_006399.2	   IOH21626	   6765	   0.49	   2.69	   9.05E-­‐03	   12%	   4%	   50	  nM	   2400	   2.8	   BATF	  
NM_007026.1	   IOH21130	   5090	   0.65	   1.40	   4.22E-­‐02	   8%	   1%	   5	  nM	   842	   6.0	   DUSP14	  
NM_007026.1	   IOH21130	   2328	   0.39	   0.75	   7.20E-­‐02	   4%	   1%	   50	  nM	   673	   3.5	   DUSP14	  
NM_007067.3	   IOH21942	   7049	   0.86	   2.82	   6.54E-­‐03	   3%	   1%	   50	  nM	   3298	   2.1	   MYST2	  
NM_014840.2	   IOH36839	   17020	   0.68	   5.35	   3.45E-­‐03	   6%	   10%	   5	  nM	   4972	   3.4	   NUAK1	  
NM_015191.1	   IOH45349	   20216	   0.83	   6.09	   1.17E-­‐03	   3%	   2%	   5	  nM	   3835	   5.3	   SNF1LK2	  
NM_015191.1	   IOH45349	   14831	   0.84	   6.21	   1.49E-­‐03	   5%	   4%	   50	  nM	   3204	   4.6	   SNF1LK2	  




NM_015978.1	   	  	   3943	   0.53	   1.46	   2.19E-­‐02	   5%	   11%	   50	  nM	   1180	   3.3	   TNNI3K	  
NM_015978.1	   	  	   4746	   0.58	   1.22	   2.52E-­‐02	   11%	   19%	   5	  nM	   1788	   2.7	   TNNI3K	  
	  	   20	  
NM_016072.2	   IOH10546	   2213	   0.40	   0.70	   7.53E-­‐02	   0%	   2%	   50	  nM	   986	   2.2	   GOLT1B	  
NM_016440.1	   	  	   2296	   0.51	   0.47	   2.14E-­‐01	   5%	   4%	   5	  nM	   1117	   2.1	   VRK3	  








NM_018328.1	   IOH12893	   2155	   0.66	   0.42	   2.49E-­‐01	   5%	   6%	   5	  nM	   289	   7.4	   MBD5	  
NM_022073.1	   IOH13327	   6798	   0.67	   1.86	   1.17E-­‐02	   9%	   0%	   5	  nM	   1423	   4.8	   EGLN3	  
NM_022073.1	   IOH13327	   23848	   0.78	   10.15	   5.61E-­‐04	   3%	   23%	   50	  nM	   6431	   3.7	   EGLN3	  
NM_024039.1	   IOH4379	   3950	   0.64	   1.46	   2.21E-­‐02	   6%	   3%	   50	  nM	   1310	   3.0	   MIS12	  
















PV3504	   	  	   25678	   0.71	   8.22	   1.59E-­‐03	   9%	   0%	   5	  nM	   8713	   2.9	   TBK1	  
PV3504	   	  	   3472	   0.84	   1.25	   3.08E-­‐02	   3%	   45%	   50	  nM	   1626	   2.1	   TBK1	  
PV3691	   	  	   20367	   0.69	   6.13	   1.22E-­‐03	   6%	   21%	   5	  nM	   940	   21.7	   ROCK1	  
PV3691	   	  	   3144	   0.88	   1.11	   3.27E-­‐02	   0%	   1%	   50	  nM	   1120	   2.8	   ROCK1	  




PV3824	   	  	   4272	   0.63	   1.07	   3.00E-­‐02	   9%	   14%	   5	  nM	   1922	   2.2	   GRK5	  
PV3836	   	  	   15152	   0.68	   4.73	   4.65E-­‐03	   10%	   11%	   5	  nM	   3204	   4.7	   IKBKB	  
PV3836	   	  	   2695	   0.89	   0.91	   4.53E-­‐02	   1%	   15%	   5	  nM	   990	   2.7	   IKBKB	  










PV3869	   	  	   4017	   0.79	   1.04	   6.30E-­‐02	   2%	   5%	   5	  nM	   1654	   2.4	   KIT	  transcript	  
	  	   21	  
	  	  




PV4211	   	  	   9708	   0.47	   2.93	   1.13E-­‐02	   9%	   5%	   5	  nM	   2400	   4.0	   MAP4K2	  
PV4211	   	  	   2293	   0.78	   0.74	   6.62E-­‐02	   4%	   23%	   50	  nM	   647	   3.5	   MAP4K2	  
PV4792	   	  	   26922	   0.84	   8.20	   6.80E-­‐04	   5%	   17%	   5	  nM	   8002	   3.4	   SNF1LK2	  
PV4877	   	  	   6157	   0.71	   1.75	   2.83E-­‐02	   8%	   20%	   5	  nM	   1608	   3.8	   ACVR1	  
PV4883	   	  	   2994	   0.61	   0.67	   6.19E-­‐02	   8%	   10%	   5	  nM	   1079	   2.8	   ACVRL1	  





















EF	  %	   %	  FS	   SVI	  ml/g	  
Baseline	  
WT-­‐Fasudil	   0.0038	   0.0162	   0.0035	   0.0113	   0.0061	   0.0028	   65.1820	   30.8120	   0.0038	  
SEM	   0.0001	   0.0008	   0.0004	   0.0008	   0.0004	   0.0004	   2.5973	   1.7259	   0.0003	  
WT-­‐Saline	   0.0036	   0.0152	   0.0031	   0.0102	   0.0055	   0.0017	   67.8775	   32.6525	   0.0038	  
SEM	   0.0003	   0.0007	   0.0004	   0.0007	   0.0004	   0.0001	   2.1391	   1.5991	   0.0004	  
cmcKO-­‐Fasudil	   0.0035	   0.0175	   0.0036	   0.0131	   0.0070	   0.0031	   55.5460	   24.7720	   0.0038	  
SEM	   0.0003	   0.0009	   0.0003	   0.0006	   0.0004	   0.0003	   3.4404	   1.9683	   0.0004	  
cmcKO-­‐Saline	   0.0032	   0.0158	   0.0031	   0.0118	   0.0066	   0.0029	   50.6606	   22.7046	   0.0036	  
SEM	   0.0006	   0.0026	   0.0005	   0.0019	   0.0011	   0.0006	   8.7211	   4.1137	   0.0007	  
p-­‐value	  WT	  vs	  cKO	   0.4390	   0.0647	   0.9133	   0.0069	   0.0029	   0.0346	   0.0044	   0.0041	   0.6616	  
4	  Weeks	  
WT-­‐Fasudil	   0.0034	   0.0173	   0.0032	   0.0120	   0.0068	   0.0026	   65.5200	   30.9580	   0.0045	  
SEM	   0.0003	   0.0010	   0.0003	   0.0007	   0.0005	   0.0003	   1.2654	   0.8764	   0.0003	  
p-­‐value	  Baseline	  vs	  4W	   0.1731	   0.0419	   0.6962	   0.2277	   0.1285	   0.7612	   0.9258	   0.9522	   0.0977	  
WT-­‐Saline	   0.0032	   0.0150	   0.0029	   0.0104	   0.0050	   0.0017	   64.7750	   30.3450	   0.0032	  
SEM	   0.0005	   0.0008	   0.0002	   0.0006	   0.0002	   0.0002	   1.0070	   0.6997	   0.0001	  
p-­‐value	  Baseline	  vs	  4W	   0.6045	   0.7238	   0.5379	   0.4949	   0.4890	   0.8590	   0.2120	   0.2117	   0.2558	  
cmcKO-­‐Fasudil	   0.0036	   0.0173	   0.0031	   0.0133	   0.0064	   0.0030	   53.0000	   23.2280	   0.0035	  
SEM	   0.0003	   0.0008	   0.0002	   0.0005	   0.0005	   0.0003	   3.1926	   1.7103	   0.0004	  
p-­‐value	  Baseline	  vs	  4W	   0.7446	   0.3887	   0.3435	   0.3304	   0.0090	   0.3337	   0.3549	   0.3536	   0.3204	  
cmcKO-­‐Saline	   0.0031	   0.0176	   0.0029	   0.0142	   0.0082	   0.0046	   44.5500	   18.8950	   0.0036	  
SEM	   0.0003	   0.0005	   0.0002	   0.0004	   0.0009	   0.0009	   5.6200	   2.8531	   0.0001	  
p-­‐value	  Baseline	  vs	  4W	   0.2214	   0.0842	   0.6275	   0.0639	   0.4938	   0.1240	   0.1827	   0.1957	   0.3698	  
p-­‐value	  WT	  Saline	  vs	  
Fasudil	   0.9247	   0.0387	   0.8162	   0.0024	   0.0116	   0.0233	   0.0122	   0.0080	   0.0672	  
p-­‐value	  cKO	  Saline	  vs	  
Fasudil	   0.7807	   0.9981	   0.8366	   0.1761	   0.5866	   0.3612	   0.0065	   0.0038	   0.0827	  
	   	   	   	   	   	   	   	   	   	   	  










msec	   PAT/ET	   TVI	  cm	  
Baseline	  
WT-­‐Fasudil	   0.0297	   10.6680	   0.8400	   0.0460	   19.6333	   20.1080	   57.4940	   35.3786	   1.8700	  
SEM	   0.0017	   0.3683	   0.0475	   0.0060	   2.8415	   1.2891	   3.7072	   2.5844	   0.1727	  
WT-­‐Saline	   0.0276	   9.8875	   0.8925	   0.0450	   19.9625	   22.2700	   58.3625	   38.0623	   2.1325	  
SEM	   0.0020	   0.4827	   0.0614	   0.0029	   1.3057	   1.8250	   2.3427	   2.1493	   0.1944	  
cmcKO-­‐Fasudil	   0.0308	   14.4460	   0.9200	   0.0300	   32.9833	   17.1400	   52.9360	   32.4109	   1.3960	  
SEM	   0.0016	   0.5700	   0.0680	   0.0045	   4.2813	   1.8103	   2.7460	   3.1585	   0.1426	  
cmcKO-­‐Saline	   0.0271	   12.4015	   0.8680	   0.0286	   29.4483	   15.6255	   47.9093	   29.6675	   1.3508	  
SEM	   0.0045	   2.1918	   0.1530	   0.0053	   5.3304	   2.8885	   7.9683	   5.0607	   0.2373	  
p-­‐value	  WT	  vs	  cKO	   0.6408	   0.0009	   0.2123	   0.0038	   0.0008	   0.0288	   0.0827	   0.1098	   0.0060	  
4	  Weeks	  
WT-­‐Fasudil	   0.0301	   9.8840	   0.8220	   0.0380	   22.0767	   15.5560	   50.8800	   30.9007	   1.9720	  
SEM	   0.0018	   0.6332	   0.0449	   0.0037	   1.2939	   1.2965	   2.1687	   3.1973	   0.1388	  
p-­‐value	  Baseline	  vs	  4W	   0.2628	   0.4603	   0.6198	   0.3375	   0.4641	   0.1386	   0.2669	   0.4262	   0.7531	  
WT-­‐Saline	   0.0278	   9.0025	   0.7800	   0.0325	   23.8958	   16.7650	   50.4775	   34.1109	   1.5900	  
SEM	   0.0017	   0.6718	   0.0842	   0.0025	   1.2423	   0.9554	   3.9011	   4.1712	   0.1165	  
p-­‐value	  Baseline	  vs	  4W	   0.6799	   0.2206	   0.0272	   0.0154	   0.0648	   0.1234	   0.1105	   0.5707	   0.0221	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cmcKO-­‐Fasudil	   0.0306	   12.4140	   0.9600	   0.0280	   36.4500	   16.1680	   44.2920	   36.6407	   1.1560	  
SEM	   0.0016	   1.2858	   0.0674	   0.0037	   5.2192	   1.0374	   1.6690	   2.5284	   0.0604	  
p-­‐value	  Baseline	  vs	  4W	   0.3034	   0.2376	   0.6077	   0.7040	   0.6906	   0.7079	   0.0858	   0.3898	   0.1666	  
cmcKO-­‐Saline	   0.0285	   13.2200	   0.9600	   0.0275	   36.0833	   17.5275	   48.0825	   36.6870	   1.4175	  
SEM	   0.0018	   1.0904	   0.0280	   0.0025	   4.3999	   0.8889	   1.5983	   2.7263	   0.1521	  
p-­‐value	  Baseline	  vs	  4W	   0.3448	   0.6803	   0.7601	   0.1817	   0.3725	   0.7515	   0.4933	   0.1937	   0.4379	  
p-­‐value	  WT	  Saline	  vs	  
Fasudil	   0.7930	   0.0165	   0.0887	   0.2070	   0.0372	   0.5803	   0.5906	   0.6237	   0.4026	  
p-­‐value	  cKO	  Saline	  vs	  
Fasudil	   0.8538	   0.1155	   0.1267	   0.0955	   0.0282	   0.7220	   0.0427	   0.1967	   0.0007	  
	  
Table	  S5.	  	  Comparison	  of	  the	  Fasudil	  treatment	  between	  Snrk	  WT	  and	  Cardiomyocyte-­‐conditional	  
SNRK	  null	  mice	  (Snrk	  cmcKO)	  –	  ECHO	  Analysis.	  ECHO	  was	  performed	  on	  6-­‐4	  month	  adult	  male	  and	  
female	  Snrk	  WT	  and	  cmcKO	  mice.	  The	  mice	  received	  daily	  injections	  of	  saline	  or	  fasudil	  as	  described	  in	  
the	  materials	  and	  methods.	  Left	  ventricular	  dimensions	  were	  normalized	  to	  body	  weight	  (BW)	  g,	  
interventricular	  septal	  end	  diastole	  (IVSd)	  cm,	  left	  ventricular	  internal	  diameter	  end	  diastole	  and	  end	  
systole	  (LVIDd,	  LVIDs)	  cm,	  left	  ventricular	  posterior	  wall	  end	  diastole	  (LVPWd)	  cm,	  end	  diastolic	  volume	  
(EDV),	  end	  systolic	  volume	  (ESV)	  parameters,	  ejection	  fraction	  (EF)	  %,	  fractional	  shortening	  (FS)	  %,	  left	  
ventricular	  mass	  in	  diastole	  (LVD	  Mass	  ASE)	  g,	  stroke	  volume	  index	  (SVI)	  ml/g,	  isovolumic	  relaxation	  time	  
(IVRT)	  msec,	  early	  mitral	  inflow	  velocity	  (E)	  m/s	  /	  early	  diastolic	  mitral	  annular	  velocity	  (e’)	  m/s,	  
pulmonary	  acceleration	  time	  (PAT)	  msec,	  ejection	  time	  (ET)	  msec	  and	  time-­‐velocity	  integral	  (TVI)	  cm.	  
There	  were	  2	  males	  and	  2-­‐3	  females	  per	  experimental	  group.	  
	  
